HomeAI · summaries
Storia in 3 fonti
Bristol Myers details Phase 3 trial win for Pomalyst successor
Bristol Myers Squibb’s next-gen multiple myeloma drug mezigdomide cut the risk of disease progression or death for certain patients by 52% when added to a treatment regimen.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
biopharmadive.com
Bristol Myers unveils data for one of its next-gen blood cancer drugs
Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
- ·
morningstar.com
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in…
Bristol Myers Squibb Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care in Relapsed or Refractory Multiple Myeloma
